Trethera News

Gloved hand of a scientist in a lab writing on a digital stilus with a digital pen.

Scientific microscope with visual representation of DNA helix

FDA Grants Fast Track Designation for TRE-515 in Combination with Radiation Therapy for the Treatment of Metastatic Castration Resistant Prostate Cancer

July 9, 2025

The FDA granted Fast Track designation to TRE‑515 in combination with precision-guided radiation therapy for metastatic castration-resistant prostate cancer (mCRPC), supporting accelerated development in one of the most aggressive forms of prostate cancer.

Read More 

Trethera Secures New License, Strengthening TRE-515 Intellectual Property Portfolio and Extending Market Exclusivity to 2045



June 3, 2025

Trethera entered an exclusive worldwide license with UCLA, strengthening TRE‑515’s intellectual property estate—which now includes new therapeutic uses—and securing U.S. and global market exclusivity through at least February 2045.

Read More 

Globally Recognized Expert in Rare Autoimmune Neurologic Diseases, Dr. Benjamin Greenberg, Joins Trethera Scientific Advisory Board



May 21, 2025

Trethera has appointed Dr. Benjamin Greenberg, a leading expert in rare autoimmune neurologic disorders, to its Scientific Advisory Board to support TRE‑515’s development in demyelinating diseases like ADEM and optic neuritis.

Read More 

Trethera To Participate in Panel Discussion and Research Poster Competition At Los Angeles Bioscience Ecosystem Summit 2025



April 22, 2025

Trethera will appear on a CEO panel and deliver a poster presentation on TRE‑515 at the 2025 Los Angeles Bioscience Ecosystem Summit, highlighting work on autoimmune disease models and fostering industry collaboration.

Read More 

Trethera Treats a Late-Stage, Heavily Pretreated Amyotrophic Lateral Sclerosis (ALS) Patient with TRE-515



March 31, 2025

Under FDA Expanded Access, Trethera treated a heavily pretreated late‑stage ALS patient with TRE‑515. Results showed disease stabilization, improved lung function and strength, no adverse events, and unanimous support to increase dosage.

Read More 